Detalles de la búsqueda
1.
Vedolizumab for the Treatment of Chronic Pouchitis.
N Engl J Med
; 388(13): 1191-1200, 2023 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988594
2.
Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.
Gastroenterology
; 166(3): 483-495, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096956
3.
Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study.
Clin Gastroenterol Hepatol
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38750870
4.
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
Clin Gastroenterol Hepatol
; 22(1): 154-163.e3, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37442318
5.
RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY.
Clin Gastroenterol Hepatol
; 2024 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38788915
6.
IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia.
Histopathology
; 84(3): 515-524, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37988281
7.
Long-term risk of delayed postoperative Crohn's disease recurrence in patients with no or mild endoscopic recurrence at first assessment.
Eur J Clin Invest
; : e14219, 2024 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38647188
8.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC Gastroenterol
; 24(1): 121, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539103
9.
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
Gut
; 72(1): 192-204, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36171081
10.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
11.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
12.
Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial.
Gastroenterology
; 163(5): 1294-1305.e3, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35940251
13.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227777
14.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35122766
15.
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
Am J Gastroenterol
; 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37753938
16.
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Am J Gastroenterol
; 118(1): 138-147, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36113491
17.
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
J Clin Gastroenterol
; 57(9): 913-919, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36227009
18.
Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study.
BMC Gastroenterol
; 23(1): 417, 2023 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38030966
19.
High Acetate Concentration Protects Intestinal Barrier and Exerts Anti-Inflammatory Effects in Organoid-Derived Epithelial Monolayer Cultures from Patients with Ulcerative Colitis.
Int J Mol Sci
; 24(1)2023 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36614212
20.
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(1): 105-115.e14, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32950748